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Background: Protein glycosylation is of fundamental importance in many biological systems. The discovery of
N-glycosylation in bacteria and the functional expression of the N-oligosaccharyltransferase PglB of Campylobacter
jejuni in Escherichia coli enabled the production of engineered glycoproteins and the study of the underlying
molecular mechanisms. A particularly promising application for protein glycosylation in recombinant bacteria is the
production of potent conjugate vaccines where polysaccharide antigens of pathogenic bacteria are covalently
bound to immunogenic carrier proteins.
Results: In this study capsular polysaccharides of the clinically relevant pathogen Staphylococcus aureus serotype 5
(CP5) were expressed in Escherichia coli and linked in vivo to a detoxified version of Pseudomonas aeruginosa
exotoxin (EPA). We investigated which amino acids of the periplasmic domain of PglB are crucial for the
glycosylation reaction using a newly established 96-well screening system enabling the relative quantification of
glycoproteins by enzyme-linked immunosorbent assay. A random mutant library was generated by error-prone PCR
and screened for inactivating amino acid substitutions. In addition to 15 inactive variants with amino acid changes
within the previously known, strictly conserved WWDYG motif of N-oligosaccharyltransferases, 8 inactivating
mutations mapped to a flexible loop in close vicinity of the amide nitrogen atom of the acceptor asparagine as
revealed in the crystal structure of the homologous enzyme C. lari PglB. The importance of the conserved loop
residue H479 for glycosylation was confirmed by site directed mutagenesis, while a change to alanine of the
adjacent, non-conserved L480 had no effect. In addition, we investigated functional requirements in the so-called
MIV motif of bacterial N-oligosaccharyltransferases. Amino acid residues I571 and V575, which had been postulated
to interact with the acceptor peptide, were subjected to cassette saturation mutagenesis. With the exception of
I571C only hydrophobic residues were found in active variants. Variant I571V performed equally well as the wild
type, cysteine at the same position reduced glycoprotein yield slightly, while a change to phenylalanine reduced
activity by a factor of three.
Conclusions: This study provides novel structure-function relationships for the periplasmic domain of the
Campylobacter jejuni N-oligosaccharyltransferase PglB and describes procedures for generating and screening
oligosaccharyltransferase mutant libraries in an engineered E. coli system.
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N-linked glycosylation is of fundamental importance for
the biological activity of many eukaryotic proteins. Bac-
terial oligosaccharyltransferases (OST) perform a similar
type of posttranslational modification in prokaryotic
cells and thus hold great promise for producing proteins
with defined glycosylation patterns in simple and cost-
efficient expression systems such as Escherichia coli [1].
The OST of Campylobacter jejuni (PglBCj) has been
functionally expressed in E. coli [2] and has been shown
to have a relaxed specificity towards its lipid-linked sub-
strate. Therefore it can be exploited, e.g., for the produc-
tion of conjugate vaccines where polysaccharide antigens
of bacterial pathogens are covalently coupled to carrier
proteins [3,4]. Polysaccharide-protein conjugates (conju-
gate vaccines) belong to the most effective measures for
combating life-threatening infectious diseases [5]. Di-
verse O-specific polysaccharides of the outer lipopoly-
saccharide layer of Gram-negative bacteria can be
efficiently coupled to carrier proteins containing a
surface-exposed D/E-X1-N-X2-T/S acceptor sequon by
PglBCj, provided that they contain an N-acetyl sugar at
the reducing end [6]. Examples are the O7, O9a, O16
and O157 antigens of E. coli, the O1 antigen of Shigella
dysenteriae as well as the O11 antigen of Pseudomonas
aeruginosa [3,4,6]. Production of conjugate vaccines by
in vivo conjugation in E. coli is much simpler than with
conventional chemical conjugation technologies, and it
has already been demonstrated that glycoconjugates can
be produced at a larger scale in fed-batch culture with
yields of 18–24 mg L-1 of purified product [4]. Recently,
it was found that capsular polysaccharides of medically
important Gram-positive bacterial pathogens such as
Staphylococcus aureus can also be transferred to ac-
ceptor proteins by PglBCj (M. Wacker and J. Lee, in
preparation).
PglBCj is a monomeric protein of 713 amino acids
and comprises 11 predicted transmembrane helixes in
the N-terminal two thirds of the polypeptide and a
globular domain at the C-terminus which is soluble and
exposed to the periplasm [7]. The latter domain of
PglBCj was crystallized by Maita et al. [8]. It harbors the
highly conserved W457WDYG461 motif which is also
found in the STT3 subunit of eukaryotic OST [2,8].
When W458 and D459 were both replaced by alanine
residues, PglBCj was rendered inactive [2]. The crystal
structure of the soluble domain of PglBCj revealed a
kinked helix opposite of the WWDYG motif which con-
tained the conserved residues M568, I571 and V575,
subsequently termed “MIV” motif of bacterial OST
[8,9]. Mutational studies confirmed the importance of
I571 for activity [8]. PglB of Campylobacter lari, a bac-
terial OST with 56% amino acid identity to PglBCj, also
glycosylates recombinant proteins in the periplasmwhen over-expressed in E. coli [10]. The crystal struc-
ture of full-length PglBC.lari was elucidated recently [11].
The structure contained a divalent metal co-factor as
well as a bound synthetic D-Q-N-A-T-p-nitro phenyl-
alanine acceptor peptide. It revealed that both the
transmembrane and the soluble periplasmic domains of
PglBC.lari participate in substrate binding and catalysis
[11]. The strictly conserved residues W463-W464-D465 of
PglBC.lari were shown to form a strong network of
hydrogen bonds with the hydroxyl group of the threo-
nine residue at position +2 relative to the glycosylated
asparagine (N) of the acceptor peptide [11]. This
explains the strict requirement for either S or T in the
D/E-X1-N-X2-S/T (X2: any amino acid except proline)
consensus sequence of bacterial N-glycosylation sites
[12,13]. Furthermore, the crystal structure indicated that
conserved residues D56, R147, D154, D156, E319, R331
and R375 of PglBC.lari are ligands of the acceptor
peptide and/or the metal cofactor. Amino acid changes
at D56, D154, E319 of PglBC.lari lead to partial or
complete loss of activity [11]. The relevance of D54
(equivalent to PglBC.lari D56) within the transmembrane
domain of PglBCj had been demonstrated previously (by
alanine replacement) [8]. A role of the MIV motif in
substrate binding is also supported by the PglBC.lari
structure because the position of the side chain of I572
(equivalent to PglBCj I571) is in agreement with a
hydrophobic interaction with the methyl group of the +2 T
residue of the acceptor peptide, presumably leading to
enhanced affinity for D-X1-N-X2-T acceptor sequons com-
pared to D-X1-N-X2-S as previously shown by Chen
et al. [14]. From the full-length structure of PglBC.lari
it was deduced that binding of acceptor proteins
occurs from one side of the protein while undecapre-
nyl-pyrophosphate-linked oligosaccharide precursors
access the active site from the other side [11]. An
elongated, flexible loop of the transmembrane domain
containing the essential amino acid E319 was
suggested to play a central role in catalysis [11]. An
in silico glycan docking experiment indicated that
conserved Y468 (PglBCj Y462) may interact with the
N-acetyl group of the innermost sugar of the transferred
oligosaccharide [11].
In this study we aimed at elucidating residues of the
periplasmic domain of PglBCj which are important for
the formation of engineered glycoconjugates. Therefore,
we established methodologies for the construction and
screening of OST variant libraries in E. coli. Two mutant
libraries generated by either error-prone PCR mutagen-
esis of the periplasmic domain or cassette mutagenesis
of specific active site residues were analyzed for inactive,
but PglB polypeptide producing variants. The obtained
results were discussed in the context of the recently
published crystal structure of the C. lari OST.
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ELISA detection of glycoconjugates
N-linked glycosylation in recombinant E. coli is a power-
ful method for obtaining conjugates of polysaccharide
antigens and immunogenic carrier proteins that can be
used as safe and efficient vaccines against bacterial
pathogens. A method for detection of glycoproteins in
the periplasm of E.coli which is suitable for medium
throughput screening has not yet been described, but is
required for the analysis of pglB mutant libraries. There-
fore, we developed an enzyme-linked immunosorbent
assay (ELISA) in 96-well format and compared the new
analytical method to the commonly used Western blot
analysis.
In this study we used a plasmid combination facilitat-
ing the biosynthesis of conjugates of Staphylococcus
aureus capsular polysaccharides type 5 (CP5) and the
carrier protein Pseudomonas aeruginosa exotoxoid A
(EPA) (M. Wacker and J. Lee, manuscript in prepar-
ation) (Table 1). In strains co-expressing CP5 from
plasmid pGVXN345 and EPA with engineered glycosyla-
tion sites from plasmid pGVXN150, while at the same
time PglBCj was provided from the low copy number
plasmid (lcp) pGVXN114, EPA-CP5 glycoconjugates
were obtained. A ladder of protein bands reacting with
anti-CP5 antibodies was detected in periplasmic extracts
of cells grown in shake flask by Western blot analysis
(Figure 1A, left panel). Similar protein ladders have been
observed previously when O-polysaccharide-protein
conjugates were produced in recombinant E. coli [3,4].
Random polysaccharide chain lengths result during O-
antigen biosynthesis by the combined action of the
enzymes Wzy and Wzz [15].
An alternative medium copy number expression vector
for PglBCj, pGVXN112Kan (Table 1) also enabled glyco-
sylation of EPA, even though glycoprotein levels were
lower (Figure 1A). When periplasmic proteins of controlTable 1 Plasmids used in this study
Plasmid Description
pACT3 Medium copy number vector for IPTG-inducible expression,
pACT3Kan Kanamycin resistance cassette inserted into chloramphenicol
pGVXN114 IPTG-inducible expression of PglB containing a hemagglutini
end, low copy number plasmid, lacI, Ptac, ori: IncW
pGVXN115 Similar to pGVXN114, but inactive PglB-HA W458A-D459A (Pg
pGVXN112Kan IPTG-inducible expression of PglB containing an HA tag at th
for mutant libraries, medium copy number
pGVXN113Kan Similar to pGVXN112Kan, but inactive PglB-HA W458A-D459A
pGVXN150 L-arabinose inducible expression of periplasmic, hexahistidine
exotoxoid A (EPA) with 2 engineered N-glycosylation sites, a
plasmid, ori: pBR322
pGVXN345 Constitutive expression of CP5 capsular polysaccharides of St
low copy number plasmid, ori: IncPastrains harboring the same combinations of EPA and
CP5 producing plasmids and expressing mutated, in-
active PglB (PglB mut: W458A-D459A) were analyzed,
no specific bands were detected (Figure 1A). However,
strong bands with the expected size of unglycosylated
EPA (MW 70 kDa) were detected in periplasmic
extracts of both wild-type PglB and mutated (mut) PglB
strains when blots were analyzed with anti-EPA anti-
bodies (Figure 1A, right panel). A ladder of proteins of a
similar size range as the ladder observed in anti-CP5
blots was also seen for wild-type PglB samples on this
blot (80–200 kDa). Anti-CP5 specific bands below the
size of EPA were most likely due to glycosylated degrad-
ation products of EPA. Such degradation products were
also observed when engineered EPA was glycosylated
with Shigella O1 polysaccharides [4].
Next we tested whether glycosylation using this system
can also be reliably detected by ELISA, as this method
could be used for the analysis of a larger number of
clones. The ELISA setup with the best signal-to-noise
ratio for periplamic extracts of E. coli comprised anti-
EPA capturing antibodies and anti-CP5 detection anti-
bodies (sandwich ELISA). ELISA absorbance values were
reproducibly and significantly higher for samples from
wild-type PglB strains compared to samples from iso-
genic control strains expressing inactive PglB (Figure 1B).
Background signals (PglB mut) were higher when the low
copy number pglB expression plasmid was used than
when the medium copy number, pACT3 derived plasmid
was used (Figure 1B). The latter plasmid was used for the
construction of pglB mutant libraries. In later experi-
ments where mutants were re-analyzed in replicates, a
second batch of anti-CP5 antibodies with a higher degree
of purity was used, which lead to a reduction of back-
ground signals to ± 0.20 (measured against air, i.e., in-
cluding absorbance of the polystyrene plate and buffer),
independent of the type of pglB expression plasmid.Selection
marker
Reference
lacI, Ptac, ori: pACYC184 Cm
R [25]
resistance gene of pACT3 KanR This study
n epitope tag (HA) at the C-terminal SpR [4]
lB mut) SpR [4]
e C-terminal end, template plasmid KanR This study
(PglB mut) KanR This study
-tagged Pseudomonas aeruginosa
raC, PBAD, high copy number
AmpR [4]
aphyloccus aureus, native promoter, TetR, CmR M. Wacker and
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Figure 1 Western blot and ELISA analysis of periplasmic
glycoproteins. Analysis of periplasmic proteins of EPA-CP5
producing E. coli strains and control strains harbouring two different
expression vectors for PglBCj. (A) Western blot of normalised
periplasmic samples, detection of glycosylated protein with anti-CP5
(left panel) and anti-EPA antisera (right panel). Theoretical molecular
weight of unglycosylated EPA: 67.4 kDa. (B) Sandwich ELISA analysis
of periplasmic samples for EPA-CP5, average values and standard
deviations of≥ 3 replicates, absorbance measured against air after
15 min development time. lcp: low copy number plasmids
pGVXN114 (wt) and pGVXN115 (mut), mcp: medium copy number
plasmids pGVXN112Kan (wt) and pGVXN113Kan (mut), mut: inactive
PglB W458A-D459A, host strain: E. coli CLM24 (pGVXN150,
pGVXN345).
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that the method is suitable for detecting and quantifying
glycoproteins in E. coli clones expressing different var-
iants of PglB. The coefficient of variation of ELISA ab-
sorbance values was below 5% of the mean value for
periplasmic extracts of strains expressing either wild-
type or inactive PglB. The lower levels of glycoproteins
produced by the strain with medium copy number plas-
mid pGVXN112Kan were reflected in lower values of
ELISA absorbance (Figure 1B).Screening system for OST mutant libraries
Based on the positive results with the sandwich ELISA
assay for shake flask samples, we developed a 96-well
cultivation and screening method for glycoprotein pro-
duction in E. coli. Screening of library clones was per-
formed in 96-well format using deep well plates (DWP)
for cultivation followed by sucrose-lysozyme extraction
of periplasmic proteins and relative quantification of
EPA-CP5 glycoconjugates by sandwich ELISA. A test
plate was inoculated with 90 clones of the EPA-CP5 pro-
ducing, wild-type PglB strain (pGVXN112Kan) and with
6 clones of the negative control strain expressing in-
active PglB mut (pGVXN113Kan). The ELISA signals of
all wells containing the wild-type PglB strain were clearly
separated from those wells which contained the inactive
control strain (Additional file 1). The average absorbance
(coefficient of variation) was 0.402 (5.1%) and 0.275
(4.5%) for wild-type and inactive PglB, respectively. The
reproducibility and sensitivity of the DWP-ELISA
screening assay was considered sufficiently high for
detecting inactivating mutations in pglB mutant
libraries.
Random mutagenesis of PglBCj by error-prone PCR
Procedures for random mutagenesis of pglBCj were also
developed in the course of this study. The periplasmic
domain (H423 to I713) was randomly mutated by error-
prone PCR (epPCR) using mutagenic DNA polymerase
Mutazyme II. The pglB plasmid library was transformed
into the expression strain which co-expressed EPA and
CP5 polysaccharides. On average 0.8 amino acid changes
were introduced within the periplasmic domain of PglB
(range 0–2) as shown when 12 randomly picked clones
were sequenced. Analysis of 5105 clones with the DWP-
ELISA screening system showed that 14.6 ± 4.3% (n = 57
plates) of variants were inactive, i.e. exhibited a
background-corrected ELISA signal which was < 20% of
the average signal of wt control wells. ELISA data for a
representative 96-well epPCR library are shown in Figure 2
(open circles, sorted with respect to detection level).
The signals of PglB mut control samples (shaded sym-
bols) always grouped with inactive clones on the right-
hand part of sorted ELISA data, while the wild-type
controls (black symbols) grouped with active clones
(Figure 2). Sequencing of 92 inactive clones without
prior analysis of PglB expression showed that 27% of
the clones harbored mutations with expected negative
effects on expression and/or activity of PglB, i.e., amino
acid substitutions within the WWDYG motif (4.4%),
mutations to a stop codon (13%), frame shift mutations
(4.4%), amino acid substitutions within the MIV motif
(1.1%) and changes to potentially structure-disrupting
proline residues (4.4%). The overall frequency of clones





















Figure 2 Screening of OST mutant libraries. Sorted ELISA
read-outs of 96-well random mutant libraries of PglBCj. Open
circles: epPCR mutagenesis of the periplasmic domain (H423-I713),
inactive clones selected for anti-HA screening and sequencing
marked by an elipsoid. Open triangles: Cassette mutagenesis of I571
and V575 using primers with NDT degeneracy, active clones
selected for sequencing marked by an elipsoid. Absorbance at
450 nm was measured against air. Filled symbols: wild-type controls
on same plate (pGVXN112Kan), shaded symbols: inactive (mut)
controls on same plate (pGVXN113Kan), host strain: E. coli CLM24
(pGVXN150-pGVXN345).
D475Y I701N D475E Y425 host
stop            pglB-
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Figure 3 Analysis of PglB expression by anti-HA Western blot.
Selected inactive clones of epPCR libraries (PglB mutations given in
lane header) and control strains were grown and induced in DWP.
wt: pGVXN112Kan, mut: pGVXN113Kan, host: E. coli CLM24
(pGVXN150, pGVXN345). Relative expression levels of full-length PglB
given in subsequent Figures and Tables were determined from the
upper, boxed bands by image analysis with the software ImageJ
(wt PglB = 100%, S = strong, W = weak, N = negative).
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PglB clones was 21.7% while 5.4% harbored silent muta-
tions in the periplasmic domain.
For elucidation of structure-function relationships only
inactivating mutations which do not abolish expression
of PglB are of interest. The vectors used for expression
of pglB and construction of mutant libraries yield re-
combinant protein with a hemagglutinin tag epitope
(HA) fused to the C-terminal end (Table 1). Several hun-
dred further epPCR clones with inactive phentotype
were screened for production of full-length PglB by anti-
HA Western blot analysis. Growth, induction and cell
lysis was performed in 96-deep well plates. For valid-
ation of the screening method, several clones with one
amino acid change were compared to stop codon
mutants as well as to wild-type and inactive control
strains on one blot. No strong anti-HA specific bands
were detected for stop codon mutants and the host
strain without pglB plasmid (Figure 3). In the case of
wild-type PglB and inactive PglB W458A-D459A (mut),
two strong bands were detected. Although the position
of the upper band was below the expected 83 kDa weassumed this band to represent full-length PglB. Due to
specific procedures required for obtaining blots of mem-
brane proteins with sufficient quality, i.e., denaturation
at 60°C instead of 95°C, membrane proteins often do not
migrate at similar positions as soluble marker proteins
in SDS-polyacrylamide gels [16]. For the homologous
membrane-bound OST of C. lari, which was expressed
with a C-terminal HA tag, the anti-HA specific bands
on Western blots were also migrating at lower positions
than the theoretical molecular mass (between 50 and
75 kDa instead of 84 kDa, [11]). The lower anti-HA
specific bands on our blot may represent the C-terminal,
globular domain of PglB generated by limited proteolysis
during expression. The theoretical molecular mass of
the periplasmic domain including the C-terminal HA
tag is 35 kDa. For quantification of relative expression
levels of PglB by image analysis only the upper band was
used. PglB expression in epPCR variants with one amino
acid change ranged from not detectable to wild-type
levels (Figure 3).
When 410 inactive clones of epPCR libraries were
screened by anti-HA Western blot analysis, it was found
that the majority (68.5%) had lost the ability to produce
any PglB, while 84 (20.5%) exhibited weak expression
and only 45 (11%) produced PglB at similar levels as the
wild-type strain. All clones showing strong PglB-specific
bands and 58 clones with weak PglB production were
sequenced. The glycosylation deficiency of the PglB posi-
tive clones was re-evaluated by DWP-ELISA and could
be confirmed in 63% of the cases (ELISA signals < 20%
of wt). In the rescreening experiment, the majority of
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nals between 20 to 50% of wild-type controls (reduced
activity variants, 28.1%) while 8.9% were identified as
false negatives (ELISA signals > 50% of wt). Single amino
acid substitutions leading to a reproducible lack of gly-
cosylation (ELISA signals < 20% of wt) without abolish-
ing production of PglB are summarized in Table 2. In
several cases, the same residues like those hit in single
mutants were found to be mutated in PglB-positive
clones with two amino acid changes (Table 2, double
mutants). Four inactivating amino acid substitutions
were identified in two or more individual clones, indicat-
ing that the diversity of the epPCR mutant library was
covered adequately. The WWDYG motif was hit in 11
single mutant clones and in four clones with two aminoTable 2 Amino acid substitutions identified in inactive
clones
Single mutants Double mutants
Mutation PglB production Mutation PglB production
V432F strong
W457S strong W457R-N582S weak
W458R strong
W458C (3x) strong




G461D strong G461D-S488P weak
















Random mutagenesis of pglBCj by epPCR was restricted to the region
encoding the periplasmic domain (H423-I713). All clones reproducibly
exhibited ELISA signals for EPA-CP5 which were≤ 20% of the wild-type
PglB control strain (pGVXN112Kan). Only results for clones which expressed
detectable amounts of PglB in DWP are shown (analysed by anti-HA Western
blot).acid changes (Table 2). A second region where inactivat-
ing mutations clustered was R465 to G481. D475 and
G481 were mutated in several clones with strong expres-
sion of PglB (Table 2).
Selected variant plasmids were isolated by mini-prep,
re-transformed into the expression strain E. coli CLM24
(pGVXN150, pGVXN345) and re-analyzed in triplicate
with the DPW-ELISA and anti-HA screening systems.
Mutation V432F reduced background-corrected EPA-
CP5 signals by 89% without any negative effect on ex-
pression of PglB (Figure 4). Change of G481 to either S
or N abolished formation of glycoconjugates completely
in spite of wild-type levels of PglB detected by anti-HA
Western blot (Figure 4). In addition to mutations Y460N
and G461D within the WWDYG motif, four other
amino acid changes lead to a complete loss of glycosyla-
tion activity: R465H, D469L, D475F and D475Y. Lack of
glycosylation in these cases cannot be explained solely
by reduced expression of the OST. There were still sub-
stantial amounts of PglB-HA detectable by anti HA
Western blot (20-50% of wt levels, Figure 4). In the case
of variants A682D and A528V, the strongly reduced
yields of EPA-CP5 are most likely related to a concomi-
tant reduction in PglB expression levels (Figure 4). As a
control, an epPCR variant with an amino acid substitu-
tion with no effect, Y645C, was also analyzed within the
same DWP-ELISA assay. For this clone, no significant



























































































Figure 4 Relative levels of glycoprotein and PglB expression in
epPCR variants. EPA-CP5 levels in periplasmic extracts of deep well
plate cultures were determined by sandwich ELISA (solid bars, left
y-axis, wt = 100%). ELISA signals were corrected for absorbance of
PglB mut control wells (ΔAbs. 450 nm). PglB production was
analysed by anti-HA Western blot of total cell protein samples (open
bars, right y-axis, band intensity of wt = 100%). Average values and
standard deviations of three replicate deep well cultures.
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resides in a non-conserved region of PglB distal to the
active site.
D475 and G481 are highly conserved in bacterial PglB
homologues (Figure 5A). In the crystal structure of
PglBC. lari the corresponding amino acids (D481 and
G487) are part of a flexible loop which is localized just
above the amide nitrogen atom of the acceptor peptide
where the covalent linkage to the reducing sugar of the
undecyprenyl-linked oligosaccharide substrate occurs































Figure 5 Structural context of inactivating mutations close to
the WWDYG motif. (A) Alignment of bacterial PglB sequences in
the region covering the C. jejuni W457WDYG461 motif to C. jejuni
G481. Numbering of ruler according to PglBC. lari, conserved residues
shaded, residues shown in B marked by arrows. (B) Position of
activity-relevant residues which were identified by epPCR of PglBCj in
the crystal structure 3RCE of PglBC. lari (bold red) [11]. The WWD
residues and conserved Y468 are shown in blue. Non-conserved,
mutation-tolerant residue L486 (C. jejuni L480) is shown in black.
Backbone structures of the periplasmic domain and membrane
domains are shown in grey and dark green, respectively. The bound
bound D-Q-N-A-T-p-nitrophenylalanine acceptor peptide is given as
atom-coloured ball-stick representation (N = position 0) and the
coordinated Mg2+ ion is shown in light green.loop we changed the conserved residue H479 (H485 in
C. lari), which is located in only 4.6 Å distance to the ac-
ceptor nitrogen atom (Figure 5B), to glutamine, an
amino acid which occurs in several distantly related
PglBCj homologues (Figure 5A). For comparison, the
adjacent, non-conserved residue L480 (L486 in C. lari)
with an upward orientation of the side chain in the C.
lari PglB crystal structure was mutated to alanine
(Figures 5A+B). The PglB H479Q variant was expressed
at wild-type levels, with anti-HA band intensities reaching
97± 23% of wild-type PglB (n = 3). However, the yield of
glycoprotein was reduced more than five-fold as deter-
mined by sandwich ELISA (16± 2.6% of background-
corrected wild-type signals, n = 3). By contrast, we did not
observe any significant difference between variant L480A
and wild-type PglBCj in EPA-CP5 and PglB levels (band
intensities on anti-HA Western blots: 127± 28% of wild-
type, background-corrected ELISA signals: 118± 0.04% of
wild-type, n = 3). In agreement with its relevance for ac-
tivity, H479 was also found to be mutated in an inactive,
PglB-positive epPCR clone with three amino acid changes
(H479R-D589E-F679I).
The epPCR experiment did not yield any variants with
reproducibly increased glycosylation efficiency; however,
numerous variants with neutral single or double muta-
tions were found, e.g., V470M, D705Y and K603E-S664R
all of which exhibited EPA-CP5 ELISA signals similar to
wild-type PglB. In contrast to residues mutated in in-
active variants, only non-conserved residues were
mutated in the latter cases.
Cassette mutagenesis of I571 and V575 (MIV motif)
Opposite of the strictly conserved WWDYG motif of
N-oligosaccharyltransferases, three conserved hydro-
phobic residues are found in bacterial enzymes which
comprise the so-called “MIV” motif [8] (amino acids
M568, I571 and V575 in PglBCj, corresponding to
M569, I572 and V576 in C. lari, Figure 6A). M568 was
hit once in the epPCR experiment, but no inactivating
mutations were recovered for I571 or V575. In order
to elucidate the plasticity and structural requirements
at these sites, random cassette mutagenesis was per-
formed. Randomization was achieved with mutagenic
primers bearing NDT degenerate codons (N = A, T, G
or C; D = A, T or G) instead of wild-type ATT and
GTG at positions I571 and V575, respectively. NDT
mutagenesis introduces codons for L, I, V, F, Y, G, S,
C, D, N, H, and R at targeted positions in gene
sequences and combines a high degree of chemical di-
versity with a relatively small library size [17]. After
confirming the success of NDT mutagenesis by se-
quencing of random clones, the pglB plasmid library
was re-transformed in the expression strain E. coli






























Figure 6 Structural context of V432 and the MIV motif. (A)
Alignment of bacterial PglB sequences in the vicinity of C. jejuni
V432 and I571/V575. Numbering of ruler according to PglBC. lari,
conserved residues shaded, residues shown in B marked by arrows.
(B) Position of residues equivalent to PglBCj V432, I571 and V575 in
the crystal structure 3RCE of PglBC.lari [11] (red). Periplasmic domain
in grey, transmembrane domain in dark green, bound D-Q-N-A-T-
p-nitrophenylalanine acceptor peptide as atom-coloured ball-stick
representation, Mg2+ ion as light-green sphere.
Table 3 Mutations tolerated at the MIV motif
PglB variant ELISA EPA-CP5 PglB polypeptide
Abs. 450 nm % of wt anti-HA, % of wt
wt 0.57 (±0.03) 100 100 (±13)
mut 0.20 (±0.01) 0 56 (±7)
I571V 0.51 (±0.05) 85 89 (±28)
I571V V575I 0.52 (±0.04) 87 85 (±11)
I571V V575L 0.46 (±0.04)* 70 84 (±7)
I571F V575L 0.32 (±0.01)* 34 96 (±31)
I571C V575I 0.41 (±0.03)* 58 65 (±13)
ELISA absorbance measured against air. Average values and standard
deviations of at least n = 3 replicate mini-well cultures.
* Significant difference to wt and mut, P value of Student’s T-test < 0.001.
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resentative 96-well library are shown in Figure 2 (open
triangles). None of the library clones exhibited
increased EPA-CP5 ELISA signals compared to the top
signal from wild-type clones of the same 96-well
screening plate. The majority of clones was inactive
(77 ± 8% of samples with an ELISA absorbance below
10% of wt, n = 6 96-well plates). Only 12 out of 590
screened library clones produced signals within the
range of wild-type control clones (e.g., clones marked
in Figure 2). Three of the active clones corresponded
to the quick change template and two clones carried
silent mutations introduced with the NDT primers, i.e.control mutation F572: TTT > TTC and V575: GTG >
GTT due to the NDT degenerate codon. In the other
active clones several single and double amino acid sub-
stitutions were identified which are listed in Table 3.
One particular substitution, I571V, was found in three
clones with one amino acid change and in two clones
with two changes. With the exception of I571C, hydro-
phobic side chains were replaced by other hydrophobic
side chains in active variants (Table 3). In comparison
to amino acids bearing hydroxyl, amine, amide or carb-
oxyl functional groups in their side chains, cystein is
non-polar/neutral.
The relative levels of EPA-CP5 and PglB were analyzed
for each type of PglB variant in replicate DWP mini-
cultures after re-transformation of the sequenced variant
plasmids (Table 3). No significant difference to wild-type
PglB was found for variants I571V and I571V-V575I, re-
spectively (Table 3). In the case of I571V -V575L, a
moderate, but significant reduction of EPA-CP5 biosyn-
thesis was observed which was not due to reduced ex-
pression of PglB (Table 3). The level of EPA-CP5
detected by ELISA was reduced by a factor of three in
variant I571F-V575L without any reduction of PglB ex-
pression, indicating that an F at position 571 has a nega-
tive effect on OST activity (Table 3). The double mutant
I571C-V575I was characterized by a parallel, moderate
reduction in the levels of both EPA-CP5 and PglB
(Table 3). The alignment of a set of diverse, non-
redundant amino acid sequences of bacterial PglB
homologues indicates that I571 and V575 are strictly
conserved in E-Proteobacteria, but not in other species
(Figure 6A). However, also in non-E-Proteobacteria
mostly hydrophobic amino acids occur at the corre-
sponding positions (Figure 6A). Isoleucine and leucine at
position PglBCj V575 were found in active variants of the
cassette mutagenesis experiment and also occur in nat-
ural PglB sequences (Figure 6A). The spatial orientation
of the equivalent residues I572 and V576 of PglBC. lari
towards the bound acceptor peptide is shown in
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are in close proximity to the methyl group of the threo-
nine residue at the N+ 2 position of the D-Q-N-A-T-p-
nitro phenylalanine acceptor peptide (Figure 6B).
Discussion
The use of bacterial OST in recombinant E. coli facili-
tates in vivo production of conjugates of polysaccharide
antigens of pathogenic bacteria and immunogenic carrier
proteins [3,4,18]. Recombinant E. coli equipped with the
oligosaccharyltransferase PglB of C. jejuni is the most
advanced system for the biotechnological production of
N-linked conjugate vaccines.
In order to gain a better understanding of residues of
PglBCj required for the glycosylation reaction we stud-
ied the effect of random mutations on the formation of
glycoconjugates composed of Pseudomonas aeruginosa
exotoxoid and Staphylococcus aureus capsular polysac-
charide CP5. Therefore, we established methods for
constructing epPCR mutant libraries of recombinant
PglB and for the screening of glycoprotein-producing
E. coli in 96-well format. Growth and induction of pglB
library clones in deep well plates followed by sandwich
ELISA analysis of the periplasmic extracts allowed a re-
liable distinction of active and inactive OST variants.
The screening of an epPCR library where the periplas-
mic domain of PglBCj had been mutagenized facilitated
the identification of previously unknown residues which
are relevant for OST activity. Apart from confirming the
importance of the well-known, strictly conserved
W457WDYG461 residues of PglBCj, the epPCR experi-
ment revealed that the region V464 to G481 immedi-
ately adjacent to this motif is also highly important
(Table 2). In the partial crystal structure of PglBCj and
the recently revealed full-length structure of PglBC.lari,
these amino acids form a flexible loop in close proximity
to the side chains of tryptophan and aspartic acid resi-
dues of the WWDYG motif [8,11]. Due to the spatial
orientation of the bound acceptor peptide and the
assumed reaction mechanism of PglB [11], this loop is
believed to interact with sugar moieties of the glycan
substrate. The highly conserved residue G481, which
was hit several times in inactive epPCR mutants, could
function as a helix breaker before the ascending helix
starting at K482, thereby providing the loop D475-G481
(C. lari D481-G487) with sufficient flexibility for inter-
action with the oligo-/polysaccharide (Figure 5B). The
inactivating mutations at G481 identified in our epPCR
experiment presumably induce structural changes which
disturb the interaction of loop residues such as H479
and D475 with the glycan substrate. In most homolo-
gous sequences which do not bear a glycine at this pos-
ition, a helix-breaking glycine or proline residue is
present at an adjacent position (Figure 5A). Our resultsfurther confirm the importance of the strictly conserved
aspartic acid residue at position 475 (C. lari D481) for
activity of PglBCj as proposed by Maita et al. [8]. In a
study using radio-labeled undecaprenyl-pyrophosphate
linked oligosacharides of C. jejuni at limiting concentra-
tions and a synthetic Ac-D-Q-N-A-T-p-nitro phenyl-
alanine acceptor peptide in excess, mutations D475E
and D475A decreased glycosylation rates of PglBCj by a
factor of four and six, respectively [19]. The negative ef-
fect of the mutations was strongest at low glycan sub-
strate concentrations [19]. Together with the reduced
activity of a K478A mutant reported by the same authors
these results support the importance of the flexible loop
D475-G481 and its probable involvement in glycan bind-
ing as suggested by our data. Judged from its distance to
the acceptor nitrogen atom (Figure 5B), the carboxylate
group of D475 might be involved in a hydrogen bond
network coordinating the C2 N-acetyl group of the in-
nermost sugar of the transferred glycan. Similarly to
eukaryotic OST, PglBCj is believed to require an N-acetyl
sugar at the reducing end for efficient transfer of poly-
and oligosaccharides to acceptor proteins [6]. The side
chain of the strictly conserved tyrosine residue at
position 462 (C. lari Y468) is in close proximity to D475
(C. lari D481) (Figure 5B). For C. lari Y468 an inter-
action with the N-acetyl group of the innermost sugar
has been suggested by others based on in silico glycan
docking [11]. The importance of the loop D475-G481 is
further backed by the phenotype of the H479Q variant
generated in this study. The side chain of the equivalent
residue H485 in PglBC.lari is spatially very close to the
nucleophilic amide nitrogen of the bound D-Q-N-A-T-
p-nitro phenylalanine acceptor peptide (Figure 5B). With
few exceptions glutamine is the only other amino acid
occurring at this position in bacterial PglB homologues
(Figure 5A). The side chain of glutamine has a similar
length as that of histidine and also contains an amino
functionality. In PglBCj glutamine seems to be able to
substitute for the function of histidine at position 479
only to a limited degree. Interestingly, removal of the ali-
phatic side chain of the adjacent, non-conserved residue
L481 by mutation to alanine had no effect on activity at
all. This is in agreement with the spatial orientation of
the side chain of the equivalent residue L486 in PglBC.lari
pointing away from the acceptor peptide (Figure 5B).
In only one inactive clone with strong expression of
pglB an amino acid change was found which mapped to
a region outside of W457 to G481. The mutation V432F
strongly reduced the glycoprotein specific ELISA signals,
but the variant was not completely inactive as EPA-CP5
formation was still detectable. Judged from the position
of the equivalent residue V438 in the crystal structure of
PglBC.lari, the bulkier and less flexible phenyl side chain
in the variant enzyme might interfere with the binding
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hindrance of the side chain of the glutamine residue at
the −1 position in D-Q-N-X-T/S sequons could play a
role (Figure 6B). In the engineered EPA used in this
study as acceptor protein two glycosylation sites had
been introduced in surface exposed loops, D-N-N-N-S
and D-Q-N-R-T. It would be interesting to study
whether glycosylation of the D-Q-N-R-T site is more
affected than that of the other site and whether a change
of −1 Q to amino acids with shorter side chains could
compensate for the negative effect of PglBCj V432F.
V432 is not strictly conserved in PglB homologues; how-
ever, in E-Proteobacteria a short “VF” motif is present at
this position in most species (Figure 6A).
The so-called MIV motif of bacterial N-oligosaccharyl-
transferases (M568, I571, V575 in PglBCj, Figure 6A)
which is assumed to interact with the acceptor peptide
was hit only once in the epPCR experiment. The side
chains of the equivalent residues I572 and V576 of
PglBC.lari are very close to the side chains of the
WWDYG motif in the crystal structure (Figure 6B).
Therefore, we specifically randomized these residues in
PglBCj using degenerate primers and screened the result-
ing focused library. Our results indicate that only few
other, chemically similar amino acids are tolerated at
these positions. Wild-type isoleucine and valine at pos-
ition 571 exhibited the same phenotype. Presumably,
both side chains allow for sufficient hydrophobic inter-
action with the methyl group of +2 T of the acceptor
sequon as suggested for PglBC.lari [11]. The strong pre-
ference for hydrophobic residues at I571 as well as V575
in active variants indicates that a hydrophobic surface
promotes binding of the polypeptide chain of the ac-
ceptor protein. In addition to I572 and V576, numerous
other surface-exposed amino acids of the acceptor pep-
tide binding pocket are also hydrophobic in PglBC.lari:
I317, M318, Y433, V438, Y466, Y468 and V575 [11].
With the exception of M318 and V575 these residues
are conserved in PglBCj (data not shown). An elongated
hydrophobic patch containing the WWDYG motif in its
center was suggested to interact with acceptor polypeptides
in the archaeal N-oligosaccharyltransferase of Pyrococcus
furiosus [20].
Directed evolution, comprising multiple rounds of ran-
dom mutagenesis, randomization of active site residues
and recombination of beneficial mutations, has proven
to be a powerful method for tuning enzymes to specific
needs, provided that suitable screening systems are avail-
able [21-23]. Theoretically, it should be possible to
evolve bacterial OSTs for enhanced activity towards
non-native polysaccharide substrates, although no such
studies have yet been reported in the literature. We did
not detect any PglB variants with increased yields of
glycoprotein in our libraries. Most likely, the number ofscreened epPCR clones was too low to find improved
variants, which are expected to be very rare. Amino acid
substitutions at the MIV motif were at best neutral,
which indicates that it is difficult to further optimize
interactions of D-X1-N-X2-S/T acceptor peptides with
PglB. However, we cannot exclude the possibility that
protein glycosylation in the applied E. coli system was
limited by other factors than OST activity, e.g., biosyn-
thesis of undecaprenyl-pyrophosphate linked polysac-
charide precursors. Furthermore, the crystal structure of
full-length PglBC.lari strongly suggests that residues of
the membrane domain are also involved in the catalytic
mechanism [11]. It might well be that an increase in
catalytic activity is not possible without simultaneous
changes both in the periplasmic and membrane domains
of PglBCj.
A general problem of enzyme engineering is the desta-
bilizing effect of introduced mutations. In the case of
PglBCj this was reflected in a high proportion of amino
acid substitutions having detrimental effects on produc-
tion and stable maintenance of the PglB polypeptide. As
conserved positions of PglBCj such as I571 and V575
were found to be particularly sensitive to changes, future
mutagenesis strategies should focus on non-conserved
residues in the vicinity of the active site. In addition,
randomization at specific positions might be restricted
to amino acids found in natural sequences as proposed
by Jochens and Bornscheuer [24], thereby reducing the
number of unwanted instable variants and thus the
screening effort.
Conclusions
In summary, this study adds important information to
structure-function relationships of bacterial OST and
provides methods for generating and screening OST
mutant libraries in E. coli strains capable of producing
engineered glycoproteins.
Methods
Bacterial strains and plasmids
Escherichia coli CLM24 (O polysaccharide ligase WaaL
negative derivative of W3110, [3]) was used as host
strain for all in vivo glycosylation experiments. For con-
struction of plasmid libraries by cassette mutagenesis, E.
coli XL10 Gold cells were used (Agilent-Stratagene, La
Jolla, CA, USA).
Plasmids used in this study are listed in Table 1. Ex-
pression vector pACT3Kan was constructed by inser-
tion of a Kanamycin resistance cassette into the cat
chloramphenicol resistance gene of pACT3 [25] by
homologous recombination. Plasmids pGVXN112Kan
and pGVXN113Kan were constructed by PCR-sub clon-
ing of the sequence coding for wt PglB with C terminal
HA tag and inactive PglB-HA W458A-D459A from
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Kan using restriction sites KpnI and BamHI. Construc-
tion of plasmid pGVXN345 for expression of the CP5
polysaccharide biosynthesis cluster of S. aureus will be
described elsewhere (GlycoVaxyn and Jean Lee, manu-
script in preparation).Expression of N-glycoproteins in shake flasks
Glycoprotein producing and control strains were culti-
vated in 100 mL Erlenmeyer flasks with 70 mL LB
medium (5 g L-1 yeast extract, 10 g L-1 casein-based
tryptone, 5 g L-1 NaCl) supplemented with 100 mg L-1
ampicillin, 30 mg L-1 kanamycin and 20 mg L-1 tetracyc-
line. Flasks were inoculated 1:100 from overnight tube
cultures and incubated at 37°C and 160 rpm. When
an OD600 of 0.5 was reached 1 mM IPTG and
2 g L-1 L-arabinose were added and 4 h later again
2 g L-1 L-arabinose. Cells were harvested after overnight
incubation by centrifugation (10’000 x g, 15 min, 4°C).
Periplasmic proteins were extracted by sucrose-lysozyme
treatment [3]. Cell pellets were resuspended to an OD600
of 20 in lysis buffer containing 20% w/v sucrose, 30 mM
TrisHCl (pH 8.0), 1 mM EDTA, 1 mg mL-1 lysozyme, 1
tablet per 80 mL of CompleteTM protease inhibitor mix
(Roche, Basel, Switzerland) and incubated for 1 h on ice
with gentle magnetic stirring. Spheroblasts with cytoplas-
mic and membrane proteins were separated by centrifuga-
tion (5000 x g, 15 min, 4°C) and the supernatant was used
for ELISA and Western blot analysis.Western blot analysis
Glycoproteins and oligosaccharyltransferase expressed
by recombinant E. coli were analyzed by SDS-PAGE and
subsequent Western blot following standard electro-
phoresis, blotting, immunoreaction and washing proce-
dures. For analysis of EPA-CP5, extracts of periplasmic
proteins were supplemented with similar volumes of 2 x
SDS PAGE sample buffer, denatured for 5 min at 95°C
and similar volumes were loaded on acrylamide gels.
EPA and EPA-CP5 glycoproteins were detected with
anti-EPA (rabbit, Sigma-Aldrich, Buchs, Switzerland)
and anti-CP5 antibodies (rabbit, GlycoVaxyn AG),
respectively.
For Western blot analysis of membrane bound PglB-
HA, total cell protein samples were prepared by resus-
pending cell pellets obtained from overnight induced
1 mL mini-cultures in deep-well plates (see below) in
100 μL of 1 x SDS-PAGE sample buffer followed by de-
naturation at 60°C for 30 min. In order to facilitate rela-
tive quantification, similar volumes of protein samples
were loaded per well (5 μL). PglB-HA protein bands
were visualized by hybridization with anti-HA antibodies
(rabbit, Sigma-Aldrich).Western blots were generally developed by
hybridization with secondary anti-rabbit IgG-HRP
antibodies (goat, Bio-Rad) followed by reaction with
Super Signal Dura West HRP substrate according
to the manufacturer’s instructions (Thermo-Scientific-
Pierce, Rockford, IL, USA). Chemiluminescence sig-
nals were recorded with a ChemiDoc-It imaging
system (UVP, Upland, CA, USA). Relative intensities
of bands specific for full-length PglB-HA (upper
bands in Figure 3) were quantified by using band area
and relative Gray values calculated with the image
analysis software ImageJ (http://rsbweb.nih.gov/ij/).
Enzyme linked immunosorbent assay (ELISA)
The relative amount of glycosylated proteins in differ-
ent periplasmic extract samples was analyzed by sand-
wich ELISA using transparent polystyrol 96-well plates
with high capacity for protein binding (F96 MaxiSorp,
Nunc). For coating with the capture antibody, wells
were filled with 60 μL of protein G purified goat-anti-
EPA antiserum (diluted in PBS to 10 μg mL-1) (US
Biological/Lucerna Chem AG, Lucerne, Switzerland)
and incubated overnight at 4°C without shaking. After
four washing steps of 2 min with 300 μL PBS contain-
ing 0.05% v/v Tween-20, wells were blocked for at
least 2 h at room temperature with 300 μL PBS con-
taining 10% w/v dry milk. Following another washing
step of 2 min with 300 μL PBS-Tween, 50 μL of peri-
plasmic extract was added per well. For hybridization
of the analyte with the capture antibodies, micro plates
were incubated overnight at 4°C. Unbound EPA/EPA-
CP5 was removed by washing the plate four times for
2 min with 300 μL PBS-Tween per well. Secondary
antibodies (rabbit anti-CP5 antiserum, GlycoVaxyn
AG) were added as 1:100 dilution in PBS + 1% dry
milk (50 μL per well), followed by incubation for at
least 1 h at room temperature and 10 rpm. Excess
antibodies were removed by four washing steps as
described above. Detection antibodies (goat-anti-rabbit
IgG-HRP, Bio-Rad, Reinach, Switzerland) were added
as 1:20’000 dilution in PBS + 1% dry milk, followed
by incubation for at least 1 h (room temperature,
10 rpm) and four final washing steps. Light-protected
ELISA plates were developed with Ultra-TMB-ELISA
HRP substrate (Thermo-Scientific/Pierce) according
to the manufacturer’s instructions. ELISA signals were
recorded at 450 nm using a Cary 50 MPR microplate
reader.
Random mutagenesis methods
Random mutations were introduced into the pglB
gene by error-prone PCR (epPCR) using mutagenic
Mutazyme II DNA polymerase (Agilent-Stratagene).
Due to the very low transformation effiency of
Ihssen et al. BMC Biotechnology 2012, 12:67 Page 12 of 13
http://www.biomedcentral.com/1472-6750/12/67spectinomycin-selectable, low copy number expres-
sion vector pGVXN114, an alternative, kanamycin-
selectable, medium copy number expression vector
(pGVXN112Kan) was used as template for the con-
struction of pglB mutant libraries. The soluble, peri-
plasmic domain of PglB (residues H423 to I713) was
amplified in 25 PCR cycles using forward primer 5’-
GCAACTATTTTGACTTTAGCTCCAGTATTTATC-3’
and reverse primer 5’-CTAGAGGATCCTTAAGCG
TAATCTGGAACATCGTATGGGTA-3’. The concen-
tration of the template plasmid was 17 ng μL-1 and
the annealing temperature was set to 55°C. PCR pro-
ducts with the expected a size of 900 bp were puri-
fied with a gel extraction kit (Sigma, Buchs,
Switzerland). Purified epPCR product was used in 50-
fold molar excess as mega primer in a quick change-
like PCR reaction (25 cycles) using high fidelity DNA
polymerase (PhusionTM, New England Biolabs, Ipswich,
MA, USA) and 1 ng μL-1 of pGVXN112Kan as tem-
plate. Methylated wt plasmid DNA was removed by
DpnI digest. Salts and reagents were removed with a
PCR clean-up kit (elution with ddH2O). Electro
competent Escherichia coli CLM24 (pGVXN150,
pGVXN345) were prepared by standard procedures
and transformed with 2 μL of purified mega primer-
quick change product using electroporation (1 mm
gap width cuvettes, 5 ms pulses of 1.8 kV). Transfor-
mants were selected on LB Agar supplemented with
100 mg L-1 ampicillin, 30 mg L-1 kanamycin and
20 mg L-1 tetracycline.
Cassette mutagenesis of I571 and V575 was per-
formed by performing quick change PCR with Phu-
sionTM polymerase (New England Biolabs). Wild-type
plasmid DNA (pGVXN112Kan, 1 ng μL-1) was ampli-
fied with mutagenic primers in 18 cycles, the annealing
temperature was 55°C. The sequences of forward and
reverse primers were 5'-T TAT ATG CCC GCT AGA
ATG TCT TTG NDT TTC TCT ACG NDT GCT AGT
TTT TCT TTT TAT TAA TTT AG-3' and 5'-CT AAA
TTA ATA AAA AGA AAA ACT AGC AHN CGT
AGA GAA AHN CAA AGA CAT TCT AGC GGG
CAT ATA A-3', respectively (mutagenized codons and
silent control mutation TTT > TTC underlined). After
DpnI digestion the PCR product was directly used for
heat shock transformation of commercial ultra-
competent E. coli XL10 Gold (Agilent-Stratagene).
Transformants were selected on LB-Kanamycin plates.
After confirming the quality of the library by sequen-
cing of randomly picked XL10 Gold clones, several
thousand XL10 Gold colonies were resuspended in
phosphate buffered saline (PBS) and mixed. The plas-
mid library was isolated with a mini-prep kit and trans-
formed into the expression strain E. coli CLM24
(pGVXN150, pGVXN345).Screening system
For mutant screening, individual E. coli clones were cul-
tivated in 96-deep well plates (DWP) with a total volume
of 2.2 mL per well (riplateTM sw 2 mL, Ritter GmbH,
Schwabmünchen, Germany). For overnight pre-cultures,
wells were filled with 0.5 mL of buffered medium con-
taining 5 g L-1 yeast extract, 10 g L-1 tryptone, 12.8 g L-1
Na2HPO47H2O, 3.0 g L-1 KH2PO4, 0.5 g L-1 NaCl,
1.0 g L-1 NH4Cl, 2 mM MgSO47H2O and 0.1 mM
CaCl2, 100 mg L
-1 ampicillin, 30 mg L-1 kanamycin and
20 mg L-1 tetracycline.
DWPs were sealed with perforated rubber-metal lids
with thin sheets of PTFE and microfiber filter material
as sterility barrier (SMCR1296 sandwich cover, system
Duetz, Kuhner AG, Birsfelden, Switzerland). Preculture
plates were inoculated with single colonies from library
transformation plates and incubated at 37°C and
500 rpm for 16–20 h in a microplate shaker (Infors AG,
Bottmingen, Switzerland). Aliquots of pre-culture plates
(100 μL) were transferred to sterile 96-well microtiter
plates (Nunc, Roskilde, Denmark), supplemented with
an equal volume of medium containing 50% v/v glycerol
and stored at −80°C.
Expression DWPs contained 1.3 mL of the medium
described above per well and were inoculated 1:50 from
pre-culture plates. Plates were incubated at 37°C and
500 rpm. OD600 was determined after 4–5 h and then
every hour with a microplate reader (Cary 50 MPR,
Varian, Palo Alto, CA, USA). At an OD600 of ≥ 0.4 expres-
sion of PglB and carrier protein was induced by adding
1 mM IPTG and 4 g L-1 L-arabinose, respectively, and
agitation was reduced to 100 rpm. After overnight incu-
bation (induction time 15–20 h) 1 mL of culture fluid per
well was transferred to a new DWP and cells were sepa-
rated by centrifugation (4000 rpm, 15 min, 4°C). Cell pel-
lets in wells were resuspended in 200 μL ice-cold
lysozyme-sucrose lysis buffer (see above). DWPs were
incubated without agitation for 1 h at 4°C and cell suspen-
sions were then transferred to a transparent microtiter
plate and centrifuged at 3000 rpm and 4°C for 15 min.
The supernatant (extract of periplasmic proteins) was
used for ELISA analysis in 96-well plates (see above).
DNA and protein sequence analysis
For analysis of library quality, plasmid mini-preps of
random clones of epPCR and cassette mutagenesis
experiments were sequenced using primers binding
within the second half of pglB (sequencing service:
GATC Biotech GmbH, Constance, Germany). Inactive
clones with positive response on PglB blots were col-
lected in new 96-well glycerol stock libraries and
sequenced using automated 96-well plasmid extrac-
tion (GATC Biotech). DNA and protein sequences
were compared to the wild-type sequence using
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(DNASTAR, Madison, WI, USA). Mutations were
manually checked for lack of ambiguity in sequencing
chromatograms. Non-redundant protein sequences
homologous to PglBCj were retrieved from a protein
BLAST search on the NCBI website and aligned using
the ClustalW algorithm of MegAlignTM. For visualisa-
tion of individual residues and spatial distances in the
3D-structure of PglB, the crystal structure file 3RCE [11]
was retrieved from Protein Data Bank and displayed
using the program Discovery Studio Visualizer 3.1
(Accelrys, Cambridge, UK).
Additional file
Additional file 1: Validation of the 96-well DWP-ELISA screening
system. Sandwich ELISA read-outs for EPA-CP5 glycoproteins and final
optical densities (600 nm) of 90 wells inoculated with individual clones of
E. coli CLM24 (pGVXN345-pGVXN150-pGVXN112Kan) (wt PglB, open
symbols) and 6 distributed wells inoculated with E. coli CLM24
(pGVXN345-pGVXN150-pGVXN113Kan) (inactive PglB, closed symbols).
ELISA absorbance at 450 nm was measured against air; OD600 was
corrected for optical density of sterile medium.
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